Month: April 2020

Invalda INVL, one of the leading asset management groups in the Baltics, will manage MD Partners, a company that has invested in Moldova-Agroindbank (MAIB), the largest commercial bank in Moldova, together with an investment fund INVL Special Opportunities Fund which is managed by INVL Asset Management.After the permission was received from the central bank of Moldova and MD Partners bonds, issued in 2018, were converted into shares, Invalda INVL holds 51.37% and INVL Special Opportunities Fund 48.63% of MD Partners shares.“We are asset managers who invest alongside our clients. That is why we invited private investors, who in 2018 invested EUR 4.5 million in INVL Special Opportunities Fund, to join the transaction in Moldova. The fund held MD Partners bonds, so investors had both the interest and the opportunity to monitor closely...

Viena pirmaujančių turto valdymo grupių Baltijos šalyse „Invalda INVL“ į didžiausią Moldovos komercinį banką „Moldova-Agroindbank“ (MAIB) investavusią bendrovę „MD Partners“ valdys kartu su investiciniu fondu „INVL Special Opportunities Fund“, kurį valdo „INVL Asset Management”.Gavus Moldovos centrinio banko leidimą ir į akcijas konvertavus 2018 m. išleistas „MD Partners“ obligacijas, „Invaldos INVL“ akcijų dalis bendrovėje „MD Partners“ siekia 51,37 proc., o „INVL Special Opportunities Fund” – 48,63 proc.„Esame turto valdytojai, investuojantys kartu su savo klientais, todėl prie sandorio Moldovoje pakvietėme prisijungti ir privačius investuotojus, kurie 2018 metais į „INVL Special Opportunities Fund“ investavo 4,5 mln. eurų. Fondas buvo įsigijęs „MD Partners“ obligacijų, todėl investuotojai turėjo ir interesą, ir galimybių atidžiai stebėti,...

COVID-19:  Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate supply levels for current approved indications;The company already increased its production capacity by 50% and is on track to further increase production over the coming months;Ongoing global clinical studies are assessing the efficacy and safety of hydroxychloroquine in the treatment of COVID-19;If the ongoing clinical studies demonstrate its safety and efficacy in COVID-19 patients, Sanofi commits to donating the medicine to governments worldwide;Sanofi CEO calls for greater international cooperation among the entire hydroxychloroquine chain, if proven safe and effective in COVID-19.Paris – April 10, 2020 – As of today, Sanofi has committed to donating...

COVID-19 : Sanofi fait don de 100 millions de doses d’hydroxychloroquine à 50 paysSanofi va fournir du Plaquenil® (hydroxychloroquine) au plus grand nombre de pays possible, tout en sécurisant le niveau de stock nécessaire pour continuer à le délivrer aux patients dans les indications actuellement approuvées.L’Entreprise a déjà augmenté sa capacité de production de 50% et prévoit de la renforcer encore dans les prochains mois.Plusieurs études cliniques internationales sont en cours pour évaluer le profil bénéfice-risque de l’hydroxychloroquine dans le traitement du COVID-19.Si les études sont concluantes, Sanofi s’engage à poursuivre le don de ce médicament aux gouvernements à travers le monde.Le Directeur Général de Sanofi appelle à une plus grande coopération internationale sur l’ensemble de la chaîne de l’hydroxychloroquine,...

Nexity’s shareholders are informed that the Combined Shareholders’ Meeting (ordinary and extraordinary) will be held on Tuesday 19 May 2020 at 10 :00 am at the company headquarter, 19 rue de Vienne – TSA 50029 – 75801 PARIS Cedex 08.In the context of Covid-19 and taking into account measures taken by the French Government to halt the spread of Covid-19, in particular the ordinance No. 2019-321 of 25 March 2020 on the adaptation of the rules of meeting and deliberation of general meetings of shareholders and governing bodies of legal entities and private entities without legal personality due to the Covid-19 epidemic, Nexity’s Board of directors has decided, on 6 April 2020, to hold the shareholders’ meeting exceptionally behind closed doors with none of its shareholders physically present.Shareholders are invited to vote by giving...

Les actionnaires de la société Nexity (la Société) sont informés qu’une Assemblée Générale Mixte (assemblée extraordinaire et ordinaire), est convoquée pour se tenir le mardi 19 mai 2020 à 10 heures au siège social de la Société, 19 rue de Vienne – TSA 50029 – 75801 PARIS Cedex 08.Dans le contexte sanitaire actuel d’épidémie de covid-19, et conformément aux dispositions adoptées par le Gouvernement pour freiner la propagation du covid-19, en particulier l’ordonnance n° 2019-321 du 25 mars 2020 portant adaptation des règles de réunion et de délibération des assemblées et organes dirigeants des personnes morales et entités dépourvues de personnalité morale de droit privé en raison de l’épidémie de covid-19, le Conseil d’administration de la Société a décidé, le 6 avril 2020, de tenir l’Assemblée Générale à huis clos hors la présence...

MONTREAL, April 09, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, has filed its Annual Information Form for the year ended December 31, 2019 today.Knight had previously announced that as a result of the COVID-19 impact, it was relying on the temporary relief afforded by DÉCISION N°2020-PDG-0023 of the Autorités des Marchés Financiers in respect of the obligation to file its Annual Information Form under National Instrument 51-102, Section 6.2.  The Company has now filed its Annual Information Form which may be found under its profile on www.sedar.com.About Knight Therapeutics Inc.

MONTRÉAL, 09 avr. 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société »), société pharmaceutique spécialisée panaméricaine (ex-ÉU) et chef de file, a déposé aujourd’hui sa notice annuelle pour l’exercice clos le 31 décembre 2019.Knight avait auparavant annoncé que suite à l’incidence de la COVID-19, la Société s’appuyait sur l’allégement temporaire accordé par la Décision N° 2020-PDG-0023 de l’Autorité des marchés financiers afférente à l’obligation de déposer sa notice annuelle en vertu de l’article 6.2 de la Norme canadienne 51-102. La Société vient de déposer sa notice annuelle qui peut être consultée sous son profil sur le site www.sedar.com.À propos de Thérapeutique Knight inc.Thérapeutique Knight inc., établie à Montréal, au Canada, est une société pharmaceutique spécialisée qui concentre...

Philadelphia, PA, April 09, 2020 (GLOBE NEWSWIRE) — Further to its new releases on February 20, 2020 and February 26, 2020, VSBLTY Groupe Technologies Corp. (the “Company” or “VSBLTY”) (CSE:VSBY))  (Frankfurt: 5VS) (OTC: VSBGF) is pleased to announce that it has closed the second tranche of its private placement (the “Offering”) of $1,000 principal amount 10% convertible unsecured debentures (the “Debentures”) for gross proceeds of $230,000, of which $200,000 was raised from the brokered portion of the Offering (the “Brokered Offering”) and $30,000 was raised from the non-brokered portion of the Offering (the “Non-Brokered Offering”). Echelon Wealth Partners Inc. (the “Agent”) acted as lead agent and sole bookrunner for the Brokered Offering.To date, the Company has raised $1,860,380 pursuant to the Offering.The Debentures will bear...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) — Resinco Capital Partners Inc. (CSE:RIN, OTC: RSCZF, FRANKFURT: L6V1) (the “Company” or “Resinco”) is pleased to announce that it has closed its previously announced non-brokered private placement on an oversubscribed basis by issuance of 25,000,000 units (the “Units” and each individually, a “Unit”) for gross proceeds of $2,500,000 (the “Offering”). Alex Somjen, president and chief executive officer of Resinco, said: “The oversubscription of our financing demonstrates the high level of demand and support we have received from the investment community. We are well positioned to explore new opportunities in health care sector, especially as it relates to detection of...